EGFR mutations in malignant pleural effusion of non-small cell lung cancer: A case report

Ming Jer Huang, Ken Hong Lim, Chin Yuan Tzen, Han Shui Hsu, Yun Yen, Biing Shiun Huang

研究成果: 雜誌貢獻文章

15 引文 (Scopus)

摘要

EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.

原文英語
頁(從 - 到)413-415
頁數3
期刊Lung Cancer
49
發行號3
DOIs
出版狀態已發佈 - 九月 1 2005
對外發佈Yes

指紋

Malignant Pleural Effusion
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
Cell Biology
Polymerase Chain Reaction
Therapeutics

ASJC Scopus subject areas

  • Oncology

引用此文

EGFR mutations in malignant pleural effusion of non-small cell lung cancer : A case report. / Huang, Ming Jer; Lim, Ken Hong; Tzen, Chin Yuan; Hsu, Han Shui; Yen, Yun; Huang, Biing Shiun.

於: Lung Cancer, 卷 49, 編號 3, 01.09.2005, p. 413-415.

研究成果: 雜誌貢獻文章

Huang, Ming Jer ; Lim, Ken Hong ; Tzen, Chin Yuan ; Hsu, Han Shui ; Yen, Yun ; Huang, Biing Shiun. / EGFR mutations in malignant pleural effusion of non-small cell lung cancer : A case report. 於: Lung Cancer. 2005 ; 卷 49, 編號 3. 頁 413-415.
@article{ed89bdcfe72748bfb959750a1dbe82d9,
title = "EGFR mutations in malignant pleural effusion of non-small cell lung cancer: A case report",
abstract = "EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.",
keywords = "Epidermal growth factor receptor, Malignant pleural effusion, Mutations, Non-small cell lung cancer, Polymerase chain reaction",
author = "Huang, {Ming Jer} and Lim, {Ken Hong} and Tzen, {Chin Yuan} and Hsu, {Han Shui} and Yun Yen and Huang, {Biing Shiun}",
year = "2005",
month = "9",
day = "1",
doi = "10.1016/j.lungcan.2005.02.016",
language = "English",
volume = "49",
pages = "413--415",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - EGFR mutations in malignant pleural effusion of non-small cell lung cancer

T2 - A case report

AU - Huang, Ming Jer

AU - Lim, Ken Hong

AU - Tzen, Chin Yuan

AU - Hsu, Han Shui

AU - Yen, Yun

AU - Huang, Biing Shiun

PY - 2005/9/1

Y1 - 2005/9/1

N2 - EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.

AB - EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.

KW - Epidermal growth factor receptor

KW - Malignant pleural effusion

KW - Mutations

KW - Non-small cell lung cancer

KW - Polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=23744438315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744438315&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.02.016

DO - 10.1016/j.lungcan.2005.02.016

M3 - Article

C2 - 15913841

AN - SCOPUS:23744438315

VL - 49

SP - 413

EP - 415

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -